Hemogenyx Pharmaceuticals PLC Announces Investor Webinar

LONDON, UK / ACCESSWIRE / June 27, 2022 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that Dr Vladislav Sandler, Chief Executive Officer & Co-Founder of Hemogenyx Pharmaceuticals, will host a live investor webinar on 6 July 2022 at 16:00 BST at which he will present an overview of the Company's activities and immediate future directions of its work, and will answer questions about the Company's current activities. If you would like to register for the webinar, please follow this link:

https://us02web.zoom.us/meeting/register/tZMudu6uqTIiGNCNbjQcZo9dL6Exyjqom-tz

After registering, you will receive a confirmation email containing information about joining the meeting.

Please submit your questions in advance and not later than 1 July 2022 by emailing hemogenyx@hemogenyx.com.

Enquiries:

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.

The Company is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.

For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. The Company's technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Hemogenyx Pharmaceuticals plc